 | Up a level |
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Cathomas, Richard; Rothermundt, Christian; Klingbiel, Dirk; Bubendorf, Lukas; Jaggi, Rolf; Betticher, Daniel C; Brauchli, Peter; Cotting, Denise; Droege, Cornelia; Winterhalder, Ralph; Siciliano, Daniele; Berthold, Dominik R; Pless, Miklos; Schiess, Ralph; von Moos, Roger; Gillessen, Silke (2012). Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clinical cancer research, 18(21), pp. 6049-57. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-2219
